公开(公告)号：US20240166741A1

公开(公告)日：2024-05-23

申请号：US18334531

申请日：2023-06-14

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A01K67/0276 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  A61K2039/507

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

公开(公告)号：US11760797B2

公开(公告)日：2023-09-19

申请号：US17199810

申请日：2021-03-12

Applicant: Genentech, Inc.

Inventor： Gerald R. Nakamura ,  Dhaya Seshasayee ,  Menno Van Lookeren Campagne ,  Tiffany Wong ,  Jia Wu ,  Hongkang Xi ,  Jack Bevers, III ,  Hiu Nam Chan ,  Laetitia Comps-Agrar ,  Racquel Corpuz

IPC: C07K16/24 ,  A61K39/395 ,  A61K39/00 ,  A61K45/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

公开(公告)号：US20210340253A1

公开(公告)日：2021-11-04

申请号：US17367094

申请日：2021-07-02

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A01K67/027 ,  C07K14/705 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

公开(公告)号：US20210332132A1

公开(公告)日：2021-10-28

申请号：US17367133

申请日：2021-07-02

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A01K67/027 ,  C07K14/705 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

公开(公告)号：US09873740B2

公开(公告)日：2018-01-23

申请号：US14333375

申请日：2014-07-16

Applicant: Genentech, Inc.

Inventor： Jane Grogan ,  Robert J. Johnston ,  Bryan Irving ,  Jason Hackney ,  Xin Yu ,  Dan Eaton ,  Kristin Bowles ,  Laetitia Comps-Agrar

IPC: C07K16/28 ,  A61K39/395 ,  A01K67/027 ,  C07K14/705 ,  A61K45/06 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0387 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2319/30 ,  Y02A50/466

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.